Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.75 |
| ▸ | AKT2 | P31751 | 14/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381015 | 0.88 | AKT1 (0.68) | AKT1AKT2LMNATSHRAKT3 | |
| SCHEMBL4371239 | 0.86 | AKT1 (0.73) | AKT1AKT2LMNATSHRCYP2D6 | |
| SCHEMBL3893832 | 0.86 | AKT1 (1.00) | AKT1AKT2 | |
| SCHEMBL5310128 | 0.83 | AKT1 (0.72) | AKT1AKT2LMNATSHRAKT3 | |
| SCHEMBL1938180 | 0.83 | AKT1 (0.65) | AKT1AKT2LMNATSHRAKT3 | |
| SCHEMBL1939083 | 0.83 | AKT1 (0.74) | AKT1AKT2LMNATSHRAKT3 | |
| SCHEMBL4371234 | 0.82 | AKT1 (0.68) | AKT1AKT2LMNATSHRAKT3 | |
| SCHEMBL4374550 | 0.82 | AKT1 (0.65) | AKT1AKT2AKT3 | |
| SCHEMBL4386805 | 0.82 | AKT1 (0.70) | AKT1AKT2AKT3 | |
| SCHEMBL1940089 | 0.81 | AKT1 (1.00) | AKT1AKT2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638530-B2 | 1-{1-[4-(3-amino-5-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; anticarcinogenic agents | MERCK & CO., INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638530-B2 | 1-{1-[4-(3-amino-5-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; anticarcinogenic agents | MERCK & CO., INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638530-B2 | 1-{1-[4-(3-amino-5-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; anticarcinogenic agents | MERCK & CO., INC. (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1620095-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20060205765-A1 | Inhibitors of akt activity | MERCK & CO., INC. (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1620095-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096130-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205765-A1 | Inhibitors of akt activity | AKT1, AKT2, PIK3CA | AKT1 1/4885AKT2 2/4885LMNA 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.